Search results
Results from the WOW.Com Content Network
Since the disease ankylosing spondylitis was still defined by the Modified New York criteria of 1984, there was the need to find a new disease term that would also include the less severe forms or early onset of ankylosing spondylitis. This expression was found in the umbrella term axial spondyloarthritis.
The BASDAI or Bath Ankylosing Spondylitis Disease Activity Index is a validated diagnostic test which allows a physician, usually a rheumatologist, to determine the effectiveness of a current drug therapy, or the need to institute a new drug therapy for the treatment of Ankylosing spondylitis (AS).
Ankylosing spondylitis (AS) is a type of arthritis from the disease spectrum of axial spondyloarthritis. [5] It is characterized by long-term inflammation of the joints of the spine, typically where the spine joins the pelvis. [2] With AS, eye and bowel problems—as well as back pain—may occur. [2]
Ankylosing spondylitis is a genetic disease with identifiable marks, tends to start showing signs in adolescence or young adulthood, is more likely to affect the lumbar spine, and affects organs. DISH has no indication of a genetic link, is primarily thoracic and does not affect organs other than the lungs, and only indirectly due to the fusion ...
Other terms for the disease have included spondylitis, but this is incorrect because it implies that the condition is inflammatory in nature, like ankylosing spondylitis. [1] The condition is likely triggered by changes in the anulus fibrosus, the tough outer ring of the intervertebral disc. This disc degeneration causes osteophytes to grow in ...
Upgrade to a faster, more secure version of a supported browser. It's free and it only takes a few moments:
Spondylitis is an inflammation of the vertebrae. It is a form of spondylopathy . In many cases, spondylitis involves one or more vertebral joints , as well, which itself is called spondylarthritis .
Pharmaceutical companies began utilizing the ASQoL to test the effectiveness of newly developed TNF inhibitors, which aid in the treatment of ankylosing spondylitis. [5] [6] Abbott has utilized the ASQoL to evaluate the impact of adalimumab [7] [8] and other organizations like Wyeth and the Medical Research Council have used it to evaluate the effect of etanercept.